Plasma Catecholamine Levels after Fluoxetine Treatment in Depressive Patients
- 1 March 2005
- journal article
- case report
- Published by S. Karger AG in Neuropsychobiology
- Vol. 51 (2) , 72-76
- https://doi.org/10.1159/000084163
Abstract
It is known that selective serotonin reuptake inhibitors, widely used as antidepressive drugs, act by inhibiting the cell reuptake of serotonin, but their effect on the catecholaminergic system is not yet completely understood. In this study, we investigated plasma concentrations of norepinephrine, epinephrine and dopamine after acute and chronic administration of fluoxetine in depressive patients. Twelve patients affected by major depression received a single oral dose of fluoxetine in the morning, 5 mg in the first 5 days, 10 mg from the 6th to the 10th day and 20 mg from the 11th to the 40th day. Twelve healthy subjects received a placebo under identical testing procedures. Blood samples were collected at baseline and 7, 10 and 24 h after drug administration on the 1st day of fluoxetine administration at a dose of 5 mg, and on the 1st and the 30th day of fluoxetine administration at a dose of 20 mg (days 11 and 40 of treatment, respectively). We found that plasma norepinephrine, epinephrine and dopamine levels significantly increased after acute and chronic treatment (p < 0.001), reaching the highest concentrations on the last day. No significant changes of these parameters were observed in control patientsKeywords
This publication has 25 references indexed in Scilit:
- Associations Between Baseline Plasma MHPG (3-methoxy-4-hydroxyphenylglycol) Levels and Clinical Responses With Respect to Milnacipran Versus Paroxetine TreatmentJournal of Clinical Psychopharmacology, 2004
- R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus An in vivo Microdialysis and Receptor Binding StudyNeuropsychopharmacology, 2002
- Plasma Levels of Catecholamine Metabolites Predict the Response to Sulpiride or Fluvoxamine in Major DepressionPharmacopsychiatry, 2002
- Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockersBritish Journal of Pharmacology, 1999
- α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving RatsJournal of Neurochemistry, 1997
- Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious ratsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1997
- Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publicationLife Sciences, 1995
- In vivo biogenic amine efflux in medial prefiontal cortex with imipramine, fluoxetine, and fluvoxamineSynapse, 1994
- Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: Microdialysis studies in the awake and anaesthetized ratNeuropharmacology, 1994
- High-affinity binding of 3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disordersLife Sciences, 1981